Long-term study of oral levosimendan for heart failure
Treatments studied
Part of Heart & circulation clinical trials.
This long-term study gives continued access to the oral levosimendan medication for people who finished the earlier TNX-103 study. The goal is to see if ongoing treatment remains safe and helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the earlier TNX-103 study.
- Your doctor must agree that continuing this treatment could help you.
- You cannot have severe liver problems (like cirrhosis or active hepatitis B or C).
- Your kidney function must be good enough (eGFR above 30).
- If you are a woman able to have children, you must use effective contraception and not be pregnant or breastfeeding.
- If you are a man, you must agree to not donate sperm during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the drug levosimendan can help people with a specific type of pulmonary hypertension (PH-HFpEF) feel less tired and breathless during daily activities, and improve their exercise ability.
This trial tests an investigational drug for people with a type of heart failure where the heart pumps normally but is stiff. The goal is to see if the drug can improve symptoms and quality of life.
This trial tests a medication called levosimendan to help people with severe heart failure who are still very short of breath even after standard treatment. The goal is to see if it can improve symptoms and help you feel better.
This study tests an experimental drug called LY3971297 to see if it can help people with chronic heart failure. It aims to find out if the drug is safe and if it improves heart function.
This study looks at how a heart medication called levosimendan works in the body of adults with severe cardiogenic shock. It aims to improve dosing for better outcomes.
This Phase 3 study continues treatment for people with pulmonary hypertension who finished an earlier parent study and have no other approved treatment option. It tests whether continuing their current medicine can help them keep getting benefit and stay safe.
Hear when a new Pulmonary Hypertension Associated With HFpEF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.